#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis


Autoři: Tara C. Bouton aff001;  Margaretha de Vos aff002;  Elizabeth J. Ragan aff004;  Laura F. White aff005;  Leonie Van Zyl aff006;  Danie Theron aff006;  C. Robert Horsburgh aff007;  Robin M. Warren aff002;  Karen R. Jacobson aff004
Působiště autorů: Division of Infectious Diseases, Brown University Alpert School of Medicine, Providence, RI, United States of America aff001;  Department of Science and Technology, National Research Foundation Centre of Excellence in Biomedical Tuberculosis Research, South Africa Medical Research Council for Tuberculosis Research, Cape Town, South Africa aff002;  Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa aff003;  Section of Infectious Diseases, Boston University School of Medicine, Boston, MA, United States of America aff004;  Department of Biostatistics Boston University School of Public Health, Boston, MA, United States of America aff005;  Brewelskloof Hospital, Worcester, South Africa aff006;  Department of Medicine, Boston University School of Medicine, Boston, MA, United States of America aff007;  Departments of Epidemiology, Biostatistics and Global Health, Boston University School of Public Health, Boston, MA, United States of America aff008
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0223308

Souhrn

South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.

Klíčová slova:

Deafness – Drug screening – Drug therapy – Extensively drug-resistant tuberculosis – Multi-drug-resistant tuberculosis – Toxicity – Tuberculosis


Zdroje

1. Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, et al. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis 2016; 62 : 418–430. doi: 10.1093/cid/civ910 26508515

2. Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother 2017; 72 : 1871–1879. doi: 10.1093/jac/dkx107 28419314

3. Guglielmetti L, Hewison C, Avaliani Z, Hughes J, Kiria N, Lomtadze N, et al. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. Int J Tuberc Lung Dis 2017; 21 : 167–174. doi: 10.5588/ijtld.16.0493 28234080

4. Nguyen TVA, Anthony RM, Bañuls A-L, Nguyen TVA, Vu DH, Alffenaar J-WC. Bedaquiline resistance: its emergence, mechanism, and prevention. Clin Infect Dis 2018; 66 : 1625–1630. doi: 10.1093/cid/cix992 29126225

5. Dheda K, Cox H, Esmail A, Wasserman S, Chang KC, Lange C. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Respirology 2018; 23 : 36–45. doi: 10.1111/resp.13143 28850767

6. Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother 2017; 72 : 684–690. doi: 10.1093/jac/dkw502 28031270

7. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018; 392 : 821–834. doi: 10.1016/S0140-6736(18)31644-1 30215381

8. Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DAet al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2018; 384 : 1005–1070.

9. WHO. Rapid Communication: Key changes to treatment of multidrug -⁠ and rifampicin-resistant tuberculosis. Geneva: 2018.

10. Department of Health Republic of South Africa. Introduction of new drugs and drug regimens for the management of drug-resistant tuberculosis in South Africa: policy framework version 1.1. 2015.

11. Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study. Clin Infect Dis 2018; ciy727.

12. Whitfield M, Soeters H, Warren R, York T, Sampson SL, Streicher EM, et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. PLoS One 2015; 10:e0133869. doi: 10.1371/journal.pone.0133869 26218737


Článek vyšel v časopise

PLOS One


2019 Číslo 10
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

BONE ACADEMY 2025
nový kurz
Autoři: prof. MUDr. Pavel Horák, CSc., doc. MUDr. Ludmila Brunerová, Ph.D, doc. MUDr. Václav Vyskočil, Ph.D., prim. MUDr. Richard Pikner, Ph.D., MUDr. Olga Růžičková, MUDr. Jan Rosa, prof. MUDr. Vladimír Palička, CSc., Dr.h.c.

Cesta pacienta nejen s SMA do nervosvalového centra
Autoři: MUDr. Jana Junkerová, MUDr. Lenka Juříková

Svět praktické medicíny 2/2025 (znalostní test z časopisu)

Eozinofilní zánět a remodelace
Autoři: MUDr. Lucie Heribanová

Hypertrofická kardiomyopatie: Moderní přístupy v diagnostice a léčbě
Autoři: doc. MUDr. David Zemánek, Ph.D., MUDr. Anna Chaloupka, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#